First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announces it has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a GI pipeline comprised of multiple, late-stage clinical assets, including latiglutenase, a potentially first-in-class, near Phase 3-ready, targeted, oral biotherapeutic for celiac disease.
Read the full article: First Wave BioPharma Announces Completion of Business Combination with ImmunogenX //
Source: https://www.globenewswire.com/news-release/2024/03/14/2846098/0/en/First-Wave-BioPharma-Announces-Completion-of-Business-Combination-with-ImmunogenX-Adding-Phase-3-Ready-Latiglutenase-to-its-Late-Stage-GI-Focused-Clinical-Pipeline.html